Terms: = Kidney tumors AND CARS, P49589, 833, ENSG00000110619 AND Treatment
22 results:
1. The Value of Dual-Energy Computed Tomography-Based Radiomics in the Evaluation of Interstitial Fibers of Clear Cell Renal Carcinoma.
Bing X; Wang N; Li Y; Sun H; Yao J; Li R; Li Z; Ouyang A
Technol Cancer Res Treat; 2024; 23():15330338241235554. PubMed ID: 38404055
[TBL] [Abstract] [Full Text] [Related]
2. HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met.
Ma H; Wei W; Liang D; Xu X; Yang D; Wang Q; Wang Y; Wei Q; Sun B; Zhao X
Immunol Invest; 2023 Nov; 52(6):735-748. PubMed ID: 37409941
[TBL] [Abstract] [Full Text] [Related]
3. Nanobody-based CAR T cells targeting intracellular tumor antigens.
Li H; Zhong D; Luo H; Shi W; Xie S; Qiang H; Zhu L; Gao L; Liu J; Sun S; Ding Z; Yang X; Lu X
Biomed Pharmacother; 2022 Dec; 156():113919. PubMed ID: 36411612
[TBL] [Abstract] [Full Text] [Related]
4. Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.
Kim TJ; Lee YH; Koo KC
Investig Clin Urol; 2022 Sep; 63(5):486-498. PubMed ID: 36067994
[TBL] [Abstract] [Full Text] [Related]
5. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract] [Full Text] [Related]
6. Effectiveness of end-stage renal disease communication skills training for healthcare personnel: a single-center, single-blind, randomized study.
Fang JT; Chen SY; Tian YC; Lee CH; Wu IW; Kao CY; Lin CC; Tang WR
BMC Med Educ; 2022 May; 22(1):397. PubMed ID: 35606757
[TBL] [Abstract] [Full Text] [Related]
7. The tricks for fighting against cancer using CAR NK cells: A review.
Vahidian F; Khosroshahi LM; Akbarzadeh M; Jahanban-Esfahlan A; Baghbanzadeh A; Ali-Hassanzadeh M; Safarzadeh E
Mol Cell Probes; 2022 Jun; 63():101817. PubMed ID: 35436564
[TBL] [Abstract] [Full Text] [Related]
8. Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the treatment of Renal Cell Carcinoma.
Panowski SH; Srinivasan S; Tan N; Tacheva-Grigorova SK; Smith B; Mak YSL; Ning H; Villanueva J; Wijewarnasuriya D; Lang S; Melton Z; Ghosh A; Dusseaux M; Galetto R; Heyen JR; Sai T; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Cancer Res; 2022 Jul; 82(14):2610-2624. PubMed ID: 35294525
[TBL] [Abstract] [Full Text] [Related]
9. CAR T cells in solid tumors: challenges and opportunities.
Marofi F; Motavalli R; Safonov VA; Thangavelu L; Yumashev AV; Alexander M; Shomali N; Chartrand MS; Pathak Y; Jarahian M; Izadi S; Hassanzadeh A; Shirafkan N; Tahmasebi S; Khiavi FM
Stem Cell Res Ther; 2021 Jan; 12(1):81. PubMed ID: 33494834
[TBL] [Abstract] [Full Text] [Related]
10. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
11. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data.
Moran M; Nickens D; Adcock K; Bennetts M; Desscan A; Charnley N; Fife K
Target Oncol; 2019 Aug; 14(4):405-416. PubMed ID: 31301015
[TBL] [Abstract] [Full Text] [Related]
12. Comparison of retroperitoneal and transperitoneal robotic partial nephrectomy for Pentafecta perioperative and renal functional outcomes.
Stroup SP; Hamilton ZA; Marshall MT; Lee HJ; Berquist SW; Hassan AS; Beksac AT; Field CA; Bloch A; Wan F; McDonald ML; Patel ND; L'Esperance JO; Derweesh IH
World J Urol; 2017 Nov; 35(11):1721-1728. PubMed ID: 28656359
[TBL] [Abstract] [Full Text] [Related]
13. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Knox JJ; Barrios CH; Kim TM; Cosgriff T; Srimuninnimit V; Pittman K; Sabbatini R; Rha SY; Flaig TW; Page RD; Beck JT; Cheung F; Yadav S; Patel P; Geoffrois L; Niolat J; Berkowitz N; Marker M; Chen D; Motzer RJ
Ann Oncol; 2017 Jun; 28(6):1339-1345. PubMed ID: 28327953
[TBL] [Abstract] [Full Text] [Related]
14. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
[TBL] [Abstract] [Full Text] [Related]
15. Reducible polyamidoamine-magnetic iron oxide self-assembled nanoparticles for doxorubicin delivery.
Chen J; Shi M; Liu P; Ko A; Zhong W; Liao W; Xing MM
Biomaterials; 2014 Jan; 35(4):1240-8. PubMed ID: 24239110
[TBL] [Abstract] [Full Text] [Related]
16. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
Iacovelli R; Palazzo A; Mezi S; Morano F; Naso G; Cortesi E
Acta Oncol; 2012 Sep; 51(7):873-9. PubMed ID: 22909392
[TBL] [Abstract] [Full Text] [Related]
17. T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
Schroten C; Kraaij R; Veldhoven JL; Berrevoets CA; den Bakker MA; Ma Q; Sadelain M; Bangma CH; Willemsen RA; Debets R
J Immunol Methods; 2010 Jul; 359(1-2):11-20. PubMed ID: 20460126
[TBL] [Abstract] [Full Text] [Related]
18. [Methodology and limits of outpatient ureteroscopy].
Arrabal Martín M; Ocete Martín C; Jiménez Pacheco A; Miján Ortiz JL; Pareja Vilches M; Zuluaga Gómez A
Arch Esp Urol; 2006 Apr; 59(3):261-72. PubMed ID: 16724711
[TBL] [Abstract] [Full Text] [Related]
19. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
[TBL] [Abstract] [Full Text] [Related]
20. The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Jpn J Cancer Res; 2000 Feb; 91(2):248-54. PubMed ID: 10761713
[TBL] [Abstract] [Full Text] [Related]
[Next]